Recently, studies in glioma xenograft models revealed that systemic administration of monoclonal antibody (9H10) to target CTLA-4 served prolonged survival in 80% of treated mice without exhibiting allergic encephalomyelitis [69]. Here, CTLA4 is linked to central nervous system cancer.